Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

NCT05879367 is registered in ClinicalTrials.gov with Orbus Therapeutics, Inc. as lead sponsor.

NCT NCT05879367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Lead sponsor
Orbus Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 24, 2023
Completion date
June 30, 2026
Enrollment
66 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, astrocytoma, idh-mutant, gbm, glioblastoma, glioblastoma idh (isocitrate dehydrogenase) wildtype, glioblastoma multiforme, glioblastoma, idh-wildtype